泛免疫炎症值在临床应用中的研究 进展

Research Advances in Pan-Immune-Inflammation Value for Clinical Applications

摘要: 泛免疫炎症值(Pan-immune-inflammation value, PIV)是一种整合中性粒细胞、血小板、单核细胞及淋巴细胞计数的综合性炎症指标，能够全面反映机体全身性免疫炎症状态。本文综述了PIV在多种疾病中的临床应用研究进展。在肿瘤领域，PIV与胃癌、食管癌、结直肠癌及乳腺癌等恶性肿瘤的预后显著相关，高PIV提示不良预后。在心血管疾病中，PIV与动脉粥样硬化易损斑块、急性心肌梗死主要不良心血管事件及心力衰竭左心室重构密切相关，具有重要的危险分层与预后评估价值。在炎症与感染性疾病中，PIV对全身炎症反应综合征、重症肺炎及脓毒症等疾病的严重程度和转归具有良好的预测效能。此外，PIV在代谢性、神经系统及肾脏疾病中也展现出潜在的应用价值。与传统的炎症指标相比，PIV在多类疾病中表现出更优的预测能力，但其临床应用仍面临临界值不统一、易受多种因素影响等挑战。未来需推进标准化建设、开展前瞻性研究，以进一步确立PIV在疾病管理中的生物标志物地位。

Abstract: The Pan-immune-inflammation value (PIV) is a comprehensive inflammatory index integrating neutrophil, platelet, monocyte, and lymphocyte counts, capable of comprehensively reflecting the body’s systemic immune-inflammatory status. This review summarizes recent advances in the clinical application of PIV across various diseases. In oncology, PIV shows significant correlation with prognosis in malignancies such as gastric, esophageal, colorectal, and breast cancers, where elevated PIV is indicative of an unfavorable prognosis. Within cardiovascular diseases, PIV is closely associated with vulnerable atherosclerotic plaques, major adverse cardiovascular events in acute myocardial infarction, and left ventricular remodeling in heart failure, holding important value for risk stratification and prognostic assessment. For inflammatory and infectious diseases, PIV demonstrates good predictive efficacy for the severity and outcomes of conditions, including systemic inflammatory response syndrome, severe pneumonia, and sepsis. Furthermore, PIV shows potential utility in metabolic, neurological, and renal disorders. Compared to traditional inflammatory markers, PIV demonstrates superior predictive capability across multiple disease categories. However, its clinical application faces challenges such as the lack of uniform cut-off values and susceptibility to various confounding factors. Future efforts should focus on promoting standardization, conducting prospective studies, and further establishing the role of PIV as a biomarker in disease management.